SWTX (NASDAQ) - SpringWorks Therapeutics

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US85205L1070
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. Web URL: https://www.springworkstx.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for SWTX (NASDAQ) - SpringWorks Therapeutics


Market Cap in USD 1,902m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1987-06-05


Fundamental -6.01
Dividend -
Performance 5y 0.20
Rel. Performance vs Sector 1.82
Analysts 4.43
Fair Price Total Ret. 27.39
Fair Price DCF todo


Growth TTM 28.39%
CAGR 5y 7.22%
CAGR / Mean Drawdown 0.19
Sharpe Ratio TTM 0.37
Alpha vs SP500 TTM 15.81
Beta vs SP500 5y weekly 0.86
CAPM 7.60%
Average Daily Range 2m 7.88%
Reversal Oscillator 99.48
Volatility GJR Garch 1y 67.30%
Price / SMA 50 32.65%
Price / SMA 200 15.55%
Current Volume 3542.8k
Average Volume 20d 1395.1k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%